A carregar...
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed
BACKGROUND: Malignant mesothelioma is a cancer which is refractory to current treatments. Imatinib mesylate is a selective inhibitor of tyrosine kinases such as bcr‐abl, c‐Kit, c‐Fms and platelet derived growth factor receptor β (PDGFRβ). PDGFRβ is often overexpressed in mesothelioma cells and is a...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Group
2007
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2117287/ https://ncbi.nlm.nih.gov/pubmed/17311837 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thx.2006.069872 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|